OTC Observer Inc reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market

Sponsored Financial Content

Latest Analysts Reports On Immune Pharmaceuticals Inc $IMNP

Recently stock market analysts have updated their consensus ratings on shares of Immune Pharmaceuticals Inc (IMNP).
The latest broker reports which have been released state 1 analyst has a rating of “buy”, 3 analysts “outperform”, 0 analysts “hold”, 0 analysts “underperform” and 0 analysts “sell”.
Most recent broker ratings
10/13/2015 – Immune Pharmaceuticals Inc had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 6.5 price target on the stock.
10/08/2015 – Roth Capital began new coverage on Immune Pharmaceuticals Inc giving the company a “buy” rating. They now have a USD 6 price target on the stock.
06/11/2015 – MLV & Co began new coverage on Immune Pharmaceuticals Inc giving the company a “buy” rating. They now have a USD 6 price target on the stock.
Immune Pharmaceuticals Inc has a 50 day moving average of 0.78 and a 200 day moving average of 1.29. The stock’s market capitalization is 18.77M, it has a 52-week low of 0.56 and a 52-week high of 2.28.
The share price of the company (IMNP) was up +6.18%, with a high of 0.65 during the day and the volume of Immune Pharmaceuticals Inc shares traded was 202235.
Immune Pharmaceuticals Inc. is a United States-based clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics, including monoclonal antibodies, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. Its pipeline includes, Bertilimumab, which is a clinical-stage human antibody, targeting eotaxin-1, which is involved in a number of immune mediated diseases; NanomAbs, which is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells, and AmiKet, which is a topical neuropathic pain drug candidate. The Company’s oncology pipeline includes Crolibulin, which is a small molecule vascular disrupting agent and apoptosis inducer for the intended treatment of patients with solid tumors, and Azixa, which is a vascular disruptive agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement

No comments:

Post a Comment

Advertisement